Javid Moslehi
Last active: 9/29/2020

Profile

Dr. Moslehi is a physician-scientist with a background in myocyte biology and myocardial response to such stresses as hypoxia, aging, and chemotherapies. He is an Assistant Professor of Cardiovascular Medicine and Oncology and is the Director of the Cardio-Oncology Program at Vanderbilt.

Dr. Moslehi graduated from Johns Hopkins University and University of Connecticut School of Medicine. He completed internship and residency in internal medicine at Johns Hopkins Hospital followed by cardiovascular and vascular medicine fellowships at the Brigham and Women's Hospital and Harvard Medical School. He then completed a post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis in heart disease. In 2009, Dr. Moslehi joined the faculty at the Harvard Medical School and founded the Cardio-Oncology program at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.

In 2014, he joined the faculty at Vanderbilt University School of Medicine where he is also the Director of the Cardio-Oncology Program. His interests in Cardio-Oncology include the cardiovascular health of cancer survivors as well as cardiotoxicities associated with novel targeted cancer therapies. His clinic is working to understand the mechanisms of toxicity associated with novel chemotherapies and is developing strategies to prevent and treat these complications. Dr. Moslehi’s primary focus in laboratory research is basic myocyte biology and myocardial adaptation to various stresses, including hypoxia, aging and chemotherapies.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, Sartor O (2020) Urol Oncol
    › Primary publication · 32958445 (PubMed)
  2. Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity. Miller JM, Meki MH, Ou Q, George SA, Gams A, Abouleisa RRE, Tang XL, Ahern BM, Giridharan GA, El-Baz A, Hill BG, Satin J, Conklin DJ, Moslehi J, Bolli R, Ribeiro AJS, Efimov IR, Mohamed TMA (2020) Toxicol Appl Pharmacol : 115213
    › Primary publication · 32877659 (PubMed)
  3. Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, Funck-Brentano E, Moslehi JJ, Johnson DB, Salem JE (2020) Annu Rev Pharmacol Toxicol
    › Primary publication · 32871087 (PubMed)
  4. Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients. Li C, Jiang J, Wang F, Zhou N, Veronese G, Moslehi JJ, Ammirati E, Wang DW (2020) J Mol Cell Cardiol : 74-87
    › Primary publication · 32827510 (PubMed) · PMC7438272 (PubMed Central)
  5. The cancer patient and cardiology. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM, Minotti G (2020) Eur J Heart Fail
    › Primary publication · 32809231 (PubMed)
  6. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients. Chen C, Wang F, Chen P, Jiang J, Cui G, Zhou N, Moroni F, Moslehi JJ, Ammirati E, Wang DW (2020) J Am Heart Assoc : e017736
    › Primary publication · 32807002 (PubMed)
  7. Crosstalk Between the Heart and Cancer: Beyond Drug Toxicity. Moslehi J, Zhang Q, Moore KJ (2020) Circulation 142(7): 684-687
    › Primary publication · 32804565 (PubMed) · PMC7436939 (PubMed Central)
  8. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, Salem JE, Wu SM, Moslehi JJ, Zhu H (2020) Annu Rev Pharmacol Toxicol
    › Primary publication · 32776859 (PubMed)
  9. Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Johnson DB, Reynolds KL, Sullivan RJ, Balko JM, Patrinely JR, Cappelli LC, Naidoo J, Moslehi JJ (2020) Lancet Oncol 21(8): e398-e404
    › Primary publication · 32758477 (PubMed)
  10. NCCN Guidelines Insights: Survivorship, Version 2.2020. Denlinger CS, Sanft T, Moslehi JJ, Overholser L, Armenian S, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Henry NL, Hill-Kayser C, Hudson M, Khakpour N, Koura D, McDonough AL, Melisko M, Mooney K, Moore HCF, Moryl N, O'Connor T, Paskett ED, Patel C, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Shockney L, Smith S, Syrjala KL, Tevaarwerk A, Zee P, McMillian NR, Freedman-Cass DA (2020) J Natl Compr Canc Netw 18(8): 1016-1023
    › Primary publication · 32755975 (PubMed)
  11. Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma. Young AC, Quach HT, Song H, Davis EJ, Moslehi JJ, Ye F, Williams GR, Johnson DB (2020) J Immunother Cancer 8(2)
    › Primary publication · 32747470 (PubMed) · PMC7398101 (PubMed Central)
  12. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Patrinely JR, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, Friedman DL, Moslehi JJ, Johnson DB (2020) Eur J Cancer : 211-220
    › Primary publication · 32599411 (PubMed) · PMC7374019 (PubMed Central)
  13. Evolving Insights into the Mechanisms of Toxicity Associated with Immune Checkpoint Inhibitor Therapy. Mangan BL, McAlister RK, Balko JM, Johnson DB, Moslehi JJ, Gibson A, Phillips EJ (2020) Br J Clin Pharmacol
    › Primary publication · 32543711 (PubMed) · PMC7444794 (PubMed Central)
  14. Vascular medicine and cardio-oncology - A new, evolving clinical frontier. Versmissen J, Power JR, Moslehi J (2020) Vasc Med 25(3): 205-207
    › Primary publication · 32539631 (PubMed)
  15. Tissue is the Issue, Even During a Pandemic. Shah KS, Moslehi JJ, Fang JC (2020) Circulation
    › Primary publication · 32539523 (PubMed)
  16. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B, Spano JP, Ederhy S, Klatzmann D, Rosenzwajg M, Fautrel B, Cadranel J, Johnson DB, Moslehi JJ, Salem JE (2020) Autoimmun Rev 19(8): 102586
    › Primary publication · 32535094 (PubMed)
  17. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D (2020) Eur J Heart Fail
    › Primary publication · 32463967 (PubMed)
  18. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database. Nguyen LS, Dolladille C, Drici MD, Fenioux C, Alexandre J, Mira JP, Moslehi JJ, Roden DM, Funck-Brentano C, Salem JE (2020) Circulation 142(3): 303-305
    › Primary publication · 32442023 (PubMed) · PMC7365677 (PubMed Central)
  19. COVID-19 and immune checkpoint inhibitors: initial considerations. Sullivan RJ, Johnson DB, Rini BI, Neilan TG, Lovly CM, Moslehi JJ, Reynolds KL (2020) J Immunother Cancer 8(1)
    › Primary publication · 32434790 (PubMed) · PMC7246104 (PubMed Central)
  20. Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective. Salem JE, Ederhy S, Lebrun-Vignes B, Moslehi JJ (2020) J Am Coll Cardiol 75(19): 2521-2523
    › Primary publication · 32408984 (PubMed)
  21. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis. Grouthier V, Lebrun-Vignes B, Moey M, Johnson DB, Moslehi JJ, Salem JE, Bachelot A (2020) Oncologist
    › Primary publication · 32390168 (PubMed) · PMC7418341 (PubMed Central)
  22. Identification of anticancer drugs associated with atrial fibrillation - analysis of the WHO pharmacovigilance database. Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, Thuny F, Ederhy S, Cohen A, Damaj G, Vilque JP, Plane AF, Legallois D, Champ-Rigot L, Milliez P, Funck-Brentano C, Dolladille C (2020) Eur Heart J Cardiovasc Pharmacother
    › Primary publication · 32353110 (PubMed)
  23. Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy. Shah KP, Song H, Ye F, Moslehi JJ, Balko JM, Salem JE, Johnson DB (2020) Cancer Immunol Res 8(7): 851-855
    › Primary publication · 32350001 (PubMed) · PMC7334081 (PubMed Central)
  24. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, Rubinstein SM, Hall R, Wyatt H, Piazza G (2020) Br J Haematol
    › Primary publication · 32314352 (PubMed)
  25. Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, Hidden-Lucet F, Hulot JS, Knollmann BC, Lebrun-Vignes B, Funck-Brentano C, Glazer AM, Roden DM (2020) Ann Endocrinol (Paris)
    › Primary publication · 32171470 (PubMed)
  26. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zlotoff DA, Murphy SP, Stone JR, Golden DLA, Alvi RM, Rokicki A, Jones-O'Connor M, Cohen JV, Heinzerling LM, Mulligan C, Armanious M, Barac A, Forrestal BJ, Sullivan RJ, Kwong RY, Yang EH, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Coelho-Filho OR, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Mercurio V, Mahmoudi M, Lawrence DP, Reynolds KL, Weinsaft JW, Baksi AJ, Ederhy S, Groarke JD, Lyon AR, Fradley MG, Thavendiranathan P, Neilan TG (2020) Eur Heart J 41(18): 1733-1743
    › Primary publication · 32112560 (PubMed) · PMC7205467 (PubMed Central)
  27. Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy. Ruddy KJ, Sangaralingham LR, Van Houten H, Nowsheen S, Sandhu N, Moslehi J, Neuman H, Jemal A, Haddad TC, Blaes AH, Villarraga HR, Thompson C, Shah ND, Herrmann J (2020) Circ Cardiovasc Qual Outcomes 13(3): e005984
    › Primary publication · 32106704 (PubMed) · PMC7101030 (PubMed Central)
  28. Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. Moey MYY, Gougis P, Goldschmidt V, Johnson DB, Lebrun-Vignes B, Moslehi J, Cadranel J, Salem JE (2020) Eur Respir J 55(6)
    › Primary publication · 32079644 (PubMed)
  29. Inflammation begets inflammation: cancer and acute MI. Kondapalli L, Moslehi J, Bonaca MP (2020) Eur Heart J 41(23): 2194-2196
    › Primary publication · 32068786 (PubMed)
  30. Solid organ transplant rejection associated with immune-checkpoint inhibitors. Saberianfar S, Nguyen LS, Manouchehri A, Lebrun-Vignes B, Moslehi JJ, Johnson DB, Hertig A, Salem JE (2020) Ann Oncol 31(4): 543-544
    › Primary publication · 32061451 (PubMed)
  31. Response by Salem et al to Letter Regarding Article, "Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes". Salem JE, Moslehi JJ, Funck Brentano C, Roden DM (2020) Circulation 141(5): e63-e64
    › Primary publication · 32011925 (PubMed) · PMC7041671 (PubMed Central)
  32. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses. Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, Salem JE, Beckman JA, Moslehi JJ (2020) Arterioscler Thromb Vasc Biol 40(3): e55-e64
    › Primary publication · 31969015 (PubMed) · PMC7047549 (PubMed Central)
  33. Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease. Aboumsallem JP, Moslehi J, de Boer RA (2020) J Am Heart Assoc 9(2): e013754
    › Primary publication · 31960736 (PubMed) · PMC7033852 (PubMed Central)
  34. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2020) Ann Oncol 31(2): 171-190
    › Primary publication · 31959335 (PubMed)
  35. Cardio-Immuno-Oncology. Zaha VG, Meijers WC, Moslehi J (2020) Circulation 141(2): 87-89
    › Primary publication · 31928434 (PubMed) · PMC7192229 (PubMed Central)
  36. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association. Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology (2020) Circulation 141(6): e69-e92
    › Primary publication · 31902242 (PubMed)
  37. Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care. Manouchehri A, Kanu E, Mauro MJ, Aday AW, Lindner JR, Moslehi J (2020) Arterioscler Thromb Vasc Biol 40(2): 301-308
    › Primary publication · 31875699 (PubMed) · PMC6993877 (PubMed Central)
  38. Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133]. Seltzer JH, Gintant G, Amiri-Kordestani L, Singer J, Koplowitz LP, Moslehi JJ, Barac A, Yu AF (2019) Am Heart J : 133
    › Primary publication · 31806089 (PubMed)
  39. Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management. Ala CK, Klein AL, Moslehi JJ (2019) Curr Cardiol Rep 21(12): 156
    › Primary publication · 31768769 (PubMed)
  40. Comparative Transcriptomics of , Patient-Derived Endothelial Cells Reveals Novel Pathways Associated With Type 2 Diabetes Mellitus. Beckman JA, Doherty SP, Feldman ZB, Banks ES, Moslehi J, Jaffe IZ, Hamburg NM, Sheng Q, Brown JD (2019) JACC Basic Transl Sci 4(5): 567-574
    › Primary publication · 31768474 (PubMed) · PMC6872769 (PubMed Central)
  41. The 2019 Nobel Prize honors fundamental discoveries in hypoxia response. Moslehi J, Rathmell WK (2020) J Clin Invest 130(1): 4-6
    › Primary publication · 31763994 (PubMed) · PMC6934228 (PubMed Central)
  42. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, Minotti G (2019) Semin Oncol 46(6): 397-402
    › Primary publication · 31753424 (PubMed)
  43. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ (2020) Urol Oncol 38(3): 83-93
    › Primary publication · 31734020 (PubMed)
  44. Need for Multidisciplinary Research and Data-Driven Guidelines for the Cardiovascular Care of Patients With Cancer. Meijers WC, Moslehi JJ (2019) JAMA 322(18): 1775-1776
    › Primary publication · 31714975 (PubMed) · PMC7228138 (PubMed Central)
  45. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, Potey C, Funck-Brentano C, Roden DM, Moslehi JJ, Salem JE (2020) Arch Cardiovasc Dis 113(1): 9-21
    › Primary publication · 31685432 (PubMed) · PMC7158843 (PubMed Central)
  46. Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. Vozy A, De Martin E, Johnson DB, Lebrun-Vignes B, Moslehi JJ, Salem JE (2019) Eur J Cancer : 112-115
    › Primary publication · 31678768 (PubMed)
  47. Cardiovascular Toxicities Associated With Ibrutinib. Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ (2019) J Am Coll Cardiol 74(13): 1667-1678
    › Primary publication · 31558250 (PubMed)
  48. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J (2019) Circulation 140(2): 80-91
    › Primary publication · 31390169 (PubMed) · PMC6779326 (PubMed Central)
  49. Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients. Das S, Pineda G, Berlin J, Hemphill B, Moslehi J, Nohria A, Fisher G (2018) J Oncol Cancer Res : 23-27
    › Primary publication · 31388651 (PubMed) · PMC6684348 (PubMed Central)
  50. Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, Hidden-Lucet F, Hulot JS, Knollmann BC, Lebrun-Vignes B, Funck-Brentano C, Glazer AM, Roden DM (2019) Circulation 140(13): 1070-1080
    › Primary publication · 31378084 (PubMed) · PMC6756939 (PubMed Central)
  51. Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, Zeiher A, Jaiswal S, Schulz C, Blankstein R, Bolton KL, Steensma D, Levine RL, Ebert BL (2019) J Am Coll Cardiol 74(4): 567-577
    › Primary publication · 31345432 (PubMed) · PMC6681657 (PubMed Central)
  52. A case report of clonal EBV-like memory CD4 T cell activation in fatal checkpoint inhibitor-induced encephalitis. Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM (2019) Nat Med 25(8): 1243-1250
    › Primary publication · 31332390 (PubMed) · PMC6689251 (PubMed Central)
  53. Fulminant Myocarditis: Evolving Diagnosis, Evolving Biology, Evolving Prognosis. Moslehi JJ, Brinkley DM, Meijers WC (2019) J Am Coll Cardiol 74(3): 312-314
    › Primary publication · 31319913 (PubMed)
  54. NCCN Guidelines Insights: Survivorship, Version 2.2019. Sanft T, Denlinger CS, Armenian S, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Mooney K, Moore HCF, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peterson L, Pirl W, Rodriguez MA, Ruddy KJ, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Zee P, McMillian NR, Freedman-Cass DA (2019) J Natl Compr Canc Netw 17(7): 784-794
    › Primary publication · 31319383 (PubMed) · PMC7094216 (PubMed Central)
  55. Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. Cadeddu Dessalvi C, Pepe A, Penna C, Gimelli A, Madonna R, Mele D, Monte I, Novo G, Nugara C, Zito C, Moslehi JJ, de Boer RA, Lyon AR, Tocchetti CG, Mercuro G (2019) Heart Fail Rev 24(6): 915-925
    › Primary publication · 31256318 (PubMed)
  56. Assessing cardiac safety in oncology drug development. Seltzer JH, Gintant G, Amiri-Kordestani L, Singer J, Koplowitz LP, Moslehi JJ, Barac A, Yu AF (2019) Am Heart J : 125-133
    › Primary publication · 31202099 (PubMed) · PMC7316329 (PubMed Central)
  57. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M (2019) N Engl J Med 380(24): 2377-2379
    › Primary publication · 31189043 (PubMed)
  58. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D (2019) J Clin Oncol 37(22): 1946-1955
    › Primary publication · 31188726 (PubMed)
  59. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. Beyer AM, Bonini MG, Moslehi J (2019) Am J Physiol Heart Circ Physiol 317(1): H164-H167
    › Primary publication · 31172808 (PubMed) · PMC6692734 (PubMed Central)
  60. Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis. Linton MF, Moslehi JJ, Babaev VR (2019) Int J Mol Sci 20(11)
    › Primary publication · 31159424 (PubMed) · PMC6600269 (PubMed Central)
  61. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem JE (2019) J Immunother Cancer 7(1): 134
    › Primary publication · 31118078 (PubMed) · PMC6530194 (PubMed Central)
  62. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis. Guerrero E, Johnson DB, Bachelot A, Lebrun-Vignes B, Moslehi JJ, Salem JE (2019) Eur J Cancer : 10-13
    › Primary publication · 30954881 (PubMed)
  63. Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A (2019) Eur J Cancer : 29-31
    › Primary publication · 30903870 (PubMed)
  64. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP (2019) J Am Coll Cardiol 73(11): 1336-1349
    › Primary publication · 30898209 (PubMed)
  65. Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need. Moslehi J, Fujiwara K, Guzik T (2019) Cardiovasc Res 115(5): 819-823
    › Primary publication · 30888396 (PubMed)
  66. Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Patton D, Harrell S, Hall R, Wyatt H, Piazza G (2019) Front Oncol : 45
    › Primary publication · 30873378 (PubMed) · PMC6401636 (PubMed Central)
  67. Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review. Calvillo-Argüelles O, Jaiswal S, Shlush LI, Moslehi JJ, Schimmer A, Barac A, Thavendiranathan P (2019) JAMA Cardiol 4(4): 380-387
    › Primary publication · 30865214 (PubMed)
  68. Hematologic Complications of Immune Checkpoint Inhibitors. Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, Lebrun-Vignes B, Moslehi JJ, Johnson DB (2019) Oncologist 24(5): 584-588
    › Primary publication · 30819785 (PubMed) · PMC6516131 (PubMed Central)
  69. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG (2019) J Immunother Cancer 7(1): 53
    › Primary publication · 30795818 (PubMed) · PMC6387531 (PubMed Central)
  70. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, Cohen P, Groarke JD, Herrmann J, Reilly CM, Weintraub NL (2019) Circulation 139(13): e579-e602
    › Primary publication · 30786722 (PubMed) · PMC6530491 (PubMed Central)
  71. The forgotten right ventricle in cardio-oncology. Jahangir E, Harinstein ME, Murthy VL, Moslehi J (2019) J Nucl Cardiol
    › Primary publication · 30771160 (PubMed) · PMC6697233 (PubMed Central)
  72. Cardiovascular toxicities associated with immune checkpoint inhibitors. Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J (2019) Cardiovasc Res 115(5): 854-868
    › Primary publication · 30715219 (PubMed) · PMC6452314 (PubMed Central)
  73. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, López JA, Lindner JR (2019) Blood 133(14): 1597-1606
    › Primary publication · 30692122 (PubMed) · PMC6450432 (PubMed Central)
  74. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA (2019) Br J Haematol 184(4): 558-569
    › Primary publication · 30506764 (PubMed) · PMC6587776 (PubMed Central)
  75. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ (2018) Lancet Oncol 19(12): 1579-1589
    › Primary publication · 30442497 (PubMed) · PMC6287923 (PubMed Central)
  76. Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution. Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y (2018) Circulation 138(7): 743-745
    › Primary publication · 30359135 (PubMed)
  77. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Pirl W, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA (2018) J Natl Compr Canc Netw 16(10): 1216-1247
    › Primary publication · 30323092 (PubMed) · PMC6438378 (PubMed Central)
  78. Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes. Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC (2018) Diabetes Care 41(12): e150-e151
    › Primary publication · 30305348 (PubMed) · PMC7301161 (PubMed Central)
  79. Bid maintains mitochondrial cristae structure and function and protects against cardiac disease in an integrative genomics study. Salisbury-Ruf CT, Bertram CC, Vergeade A, Lark DS, Shi Q, Heberling ML, Fortune NL, Okoye GD, Jerome WG, Wells QS, Fessel J, Moslehi J, Chen H, Roberts LJ, Boutaud O, Gamazon ER, Zinkel SS (2018) Elife
    › Primary publication · 30281024 (PubMed) · PMC6234033 (PubMed Central)
  80. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) JAMA Oncol 4(12): 1721-1728
    › Primary publication · 30242316 (PubMed) · PMC6440712 (PubMed Central)
  81. Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers. Blaes AH, Thavendiranathan P, Moslehi J (2018) Am Soc Clin Oncol Educ Book : 764-774
    › Primary publication · 30231407 (PubMed)
  82. Immune checkpoint inhibitors and cardiovascular toxicity. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J (2018) Lancet Oncol 19(9): e447-e458
    › Primary publication · 30191849 (PubMed)
  83. Cardio-Oncology: Time to Get More Mechanistic. Moslehi J, Lenihan DJ (2017) JACC Basic Transl Sci 2(1): 54-55
    › Primary publication · 30167554 (PubMed) · PMC6113550 (PubMed Central)
  84. Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Lancet 392(10145): 384-385
    › Primary publication · 30102170 (PubMed)
  85. Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, Moslehi JJ, Badilini F, Haroche J, Gougis P, Fressart V, Glazer AM, Hidden-Lucet F, Touraine P, Lebrun-Vignes B, Roden DM, Bachelot A, Funck-Brentano C (2018) Circulation 138(1): 110-113
    › Primary publication · 29967236 (PubMed) · PMC6053686 (PubMed Central)
  86. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, Moslehi J, Mulrooney DA, Nathan PC, Ryan TD, van der Pal HJ, van Dalen EC, Kremer LCM (2018) J Clin Oncol 36(21): 2135-2144
    › Primary publication · 29874141 (PubMed) · PMC6804893 (PubMed Central)
  87. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, Hariharan S, Hammad TA, Lindenfeld J, Murphy MJ, Moslehi JJ, Checkpoint Inhibitor Safety Working Group (2018) Oncologist 23(8): 874-878
    › Primary publication · 29802220 (PubMed) · PMC6156187 (PubMed Central)
  88. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, Courtillot C, Bachelot A, Roden DM, Moslehi JJ, Salem JE (2018) Heart 104(22): 1859-1863
    › Primary publication · 29720397 (PubMed)
  89. In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers. Cai C, Fang J, Guo P, Wang Q, Hong H, Moslehi J, Cheng F (2018) J Chem Inf Model 58(5): 943-956
    › Primary publication · 29712429 (PubMed) · PMC5975252 (PubMed Central)
  90. Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE (2018) Pharmacol Ther : 89-103
    › Primary publication · 29698683 (PubMed)
  91. Autochthonous tumors driven by loss have an ongoing requirement for the RBP2 histone demethylase. McBrayer SK, Olenchock BA, DiNatale GJ, Shi DD, Khanal J, Jennings RB, Novak JS, Oser MG, Robbins AK, Modiste R, Bonal D, Moslehi J, Bronson RT, Neuberg D, Nguyen QD, Signoretti S, Losman JA, Kaelin WG (2018) Proc Natl Acad Sci U S A 115(16): E3741-E3748
    › Primary publication · 29610306 (PubMed) · PMC5910822 (PubMed Central)
  92. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG (2018) J Am Coll Cardiol 71(16): 1755-1764
    › Primary publication · 29567210 (PubMed) · PMC6196725 (PubMed Central)
  93. Inhibition of the -Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic. Yang T, Meoli DF, Moslehi J, Roden DM (2018) J Pharmacol Exp Ther 365(3): 460-466
    › Primary publication · 29563327 (PubMed) · PMC5931436 (PubMed Central)
  94. Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment. Spetz J, Moslehi J, Sarosiek K (2018) Curr Treat Options Cardiovasc Med 20(4): 31
    › Primary publication · 29556748 (PubMed) · PMC7325164 (PubMed Central)
  95. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Lancet 391(10124): 933
    › Primary publication · 29536852 (PubMed) · PMC6668330 (PubMed Central)
  96. Comorbidities: Cardiovascular disease and breast cancer. Moey M, Moslehi J (2018) Nat Rev Cardiol 15(4): 200-202
    › Primary publication · 29532794 (PubMed)
  97. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it? Stack JP, Moslehi J, Sayed N, Wu JC (2019) Eur Heart J 40(22): 1764-1770
    › Primary publication · 29377985 (PubMed) · PMC6554650 (PubMed Central)
  98. The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, Choueiri TK, McKay RR (2018) Clin Genitourin Cancer 16(2): e327-e333
    › Primary publication · 29361425 (PubMed)
  99. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J (2018) Hypertension 71(2): e1-e8
    › Primary publication · 29279311 (PubMed) · PMC5825002 (PubMed Central)
  100. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Barber MC, Mauro MJ, Moslehi J (2017) Hematology Am Soc Hematol Educ Program 2017(1): 110-114
    › Primary publication · 29222244 (PubMed) · PMC6142546 (PubMed Central)
  101. Smoldering myocarditis following immune checkpoint blockade. Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM (2017) J Immunother Cancer 5(1): 91
    › Primary publication · 29157297 (PubMed) · PMC5697345 (PubMed Central)
  102. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J (2018) Br J Haematol 180(2): 271-275
    › Primary publication · 29048105 (PubMed)
  103. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR (2017) J Natl Compr Canc Netw 15(9): 1140-1163
    › Primary publication · 28874599 (PubMed) · PMC5865602 (PubMed Central)
  104. Loss of the melanocortin-4 receptor in mice causes dilated cardiomyopathy. Litt MJ, Okoye GD, Lark D, Cakir I, Moore C, Barber MC, Atkinson J, Fessel J, Moslehi J, Cone RD (2017) Elife
    › Primary publication · 28829041 (PubMed) · PMC5577919 (PubMed Central)
  105. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Kipps TJ, Coutre S, Dilhuydy MS, Cramer P, Tedeschi A, Jaeger U, Dreyling M, Byrd JC, Howes A, Todd M, Vermeulen J, James DF, Clow F, Styles L, Valentino R, Wildgust M, Mahler M, Burger JA (2017) Haematologica 102(10): 1796-1805
    › Primary publication · 28751558 (PubMed) · PMC5622864 (PubMed Central)
  106. 21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine. Sheng CC, Amiri-Kordestani L, Palmby T, Force T, Hong CC, Wu JC, Croce K, Kim G, Moslehi J (2016) JACC Basic Transl Sci 1(5): 386-398
    › Primary publication · 28713868 (PubMed) · PMC5508213 (PubMed Central)
  107. Grounding Cardio-Oncology in Basic and Clinical Science. Moslehi J, Amgalan D, Kitsis RN (2017) Circulation 136(1): 3-5
    › Primary publication · 28674089 (PubMed) · PMC5535811 (PubMed Central)
  108. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG (2017) Br J Haematol 178(4): 547-560
    › Primary publication · 28466536 (PubMed) · PMC6812508 (PubMed Central)
  109. Cardio-Oncology: Vascular Endothelial Growth Factor Inhibitors, Salt, and Macrophages: A Complicated Interaction. Moslehi J, Pandey AK, Bhatia N (2017) Hypertension 69(5): 785-786
    › Primary publication · 28320853 (PubMed)
  110. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Sethi TK, Basdag B, Bhatia N, Moslehi J, Reddy NM (2017) Curr Hematol Malig Rep 12(3): 257-267
    › Primary publication · 28233150 (PubMed)
  111. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR (2017) Blood 129(18): 2581-2584
    › Primary publication · 28223277 (PubMed) · PMC7219062 (PubMed Central)
  112. Cardiovascular Toxicities Associated with Cancer Immunotherapies. Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ (2017) Curr Cardiol Rep 19(3): 21
    › Primary publication · 28220466 (PubMed)
  113. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sharma A, Burridge PW, McKeithan WL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T, Wu H, Holmström A, Matsa E, Zhang Y, Kumar A, Fan AC, Del Álamo JC, Wu SM, Moslehi JJ, Mercola M, Wu JC (2017) Sci Transl Med 9(377)
    › Primary publication · 28202772 (PubMed) · PMC5409837 (PubMed Central)
  114. Myocarditis with Immune Checkpoint Blockade. Moslehi JJ, Johnson DB, Sosman JA (2017) N Engl J Med 376(3): 292
    › Primary publication · 28099832 (PubMed)
  115. Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson S, Moslehi J, Letai A (2017) Cancer Cell 31(1): 142-156
    › Primary publication · 28017613 (PubMed) · PMC5363285 (PubMed Central)
  116. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D (2017) J Clin Oncol 35(8): 893-911
    › Primary publication · 27918725 (PubMed)
  117. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ (2016) N Engl J Med 375(18): 1749-1755
    › Primary publication · 27806233 (PubMed) · PMC5247797 (PubMed Central)
  118. Cardiovascular Toxic Effects of Targeted Cancer Therapies. Moslehi JJ (2016) N Engl J Med 375(15): 1457-1467
    › Primary publication · 27732808 (PubMed)
  119. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, Richardson PG, Moslehi J (2017) JAMA Oncol 3(7): 980-988
    › Primary publication · 27632640 (PubMed)
  120. NCCN Guidelines Insights: Survivorship, Version 1.2016. Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, Ku GH, Kvale E, Langbaum TS, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Sanft T, Silverman P, Smith S, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA (2016) J Natl Compr Canc Netw 14(6): 715-24
    › Primary publication · 27283164 (PubMed) · PMC5865597 (PubMed Central)
  121. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. Truong SR, Barry WT, Moslehi JJ, Baker EL, Mayer EL, Partridge AH (2016) Oncologist 21(6): 666-70
    › Primary publication · 27107002 (PubMed) · PMC4912366 (PubMed Central)
  122. EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection. Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG (2016) Cell 165(2): 497
    › Primary publication · 27058668 (PubMed)
  123. Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G, Lenneman CG, Magalhaes A, Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J (2016) J Card Fail 22(6): 465-71
    › Primary publication · 27038642 (PubMed)
  124. Cardiovascular Complications of Novel Multiple Myeloma Treatments. Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J (2016) Circulation 133(9): 908-12
    › Primary publication · 26927008 (PubMed)
  125. EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection. Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG (2016) Cell 164(5): 884-95
    › Primary publication · 26919427 (PubMed) · PMC4819986 (PubMed Central)
  126. Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J (2016) Circulation 133(5): 537-41
    › Primary publication · 26831435 (PubMed) · PMC5029929 (PubMed Central)
  127. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ (2015) Circulation 132(23): 2248-58
    › Primary publication · 26644247 (PubMed) · PMC4863699 (PubMed Central)
  128. Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training. Scott JM, Armenian S, Giralt S, Moslehi J, Wang T, Jones LW (2016) Crit Rev Oncol Hematol : 222-34
    › Primary publication · 26643524 (PubMed) · PMC5003053 (PubMed Central)
  129. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM (2016) JAMA Oncol 2(1): 29-36
    › Primary publication · 26539793 (PubMed) · PMC5654518 (PubMed Central)
  130. Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. Guan J, Khambhati J, Jones LW, Morgans A, Allaf M, Penson DF, Moslehi J (2015) Circulation 132(18): e218-20
    › Primary publication · 26527696 (PubMed) · PMC5004633 (PubMed Central)
  131. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. Moslehi JJ, Deininger M (2015) J Clin Oncol 33(35): 4210-8
    › Primary publication · 26371140 (PubMed) · PMC4658454 (PubMed Central)
  132. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J (2015) J Am Coll Cardiol 66(10): 1160-78
    › Primary publication · 26337996 (PubMed)
  133. QT Prolongation and Oncology Drug Development. Fradley MG, Moslehi J (2015) Card Electrophysiol Clin 7(2): 341-55
    › Primary publication · 26002398 (PubMed)
  134. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. Groarke JD, Tanguturi VK, Hainer J, Klein J, Moslehi JJ, Ng A, Forman DE, Di Carli MF, Nohria A (2015) J Am Coll Cardiol 65(6): 573-83
    › Primary publication · 25677317 (PubMed)
  135. ABCDE steps to prevent heart disease in breast cancer survivors. Montazeri K, Unitt C, Foody JM, Harris JR, Partridge AH, Moslehi J (2014) Circulation 130(18): e157-9
    › Primary publication · 25462826 (PubMed)
  136. Survivorship: screening for cancer and treatment effects, version 2.2014. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA (2014) J Natl Compr Canc Netw 12(11): 1526-31
    › Primary publication · 25361799 (PubMed) · PMC4771020 (PubMed Central)
  137. Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA, National Comprehensive Cancer Network (2014) J Natl Compr Canc Netw 12(10): 1396-406
    › Primary publication · 25313179 (PubMed) · PMC4465236 (PubMed Central)
  138. Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary. Koelwyn GJ, Jones LW, Moslehi J (2014) J Am Coll Cardiol 64(13): 1320-2
    › Primary publication · 25257632 (PubMed)
  139. Survivorship: healthy lifestyles, version 2.2014. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA, National comprehensive cancer network (2014) J Natl Compr Canc Netw 12(9): 1222-37
    › Primary publication · 25190692 (PubMed) · PMC4465248 (PubMed Central)
  140. Survivorship: immunizations and prevention of infections, version 2.2014. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA (2014) J Natl Compr Canc Netw 12(8): 1098-111
    › Primary publication · 25099442 (PubMed) · PMC4465238 (PubMed Central)
  141. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J (2014) Curr Treat Options Cardiovasc Med 16(9): 335
    › Primary publication · 25099086 (PubMed)
  142. The challenge of cross-trial comparisons using limited data. Laubach JP, Faber EA, Voorhees P, Moslehi J, Varga C, Niculescu L, Anderson KC, Richardson PG (2014) Haematologica 99(8): e145-6
    › Primary publication · 25082787 (PubMed) · PMC4116848 (PubMed Central)
  143. Survivorship: cognitive function, version 1.2014. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA, National Comprehensive Cancer Network (2014) J Natl Compr Canc Netw 12(7): 976-86
    › Primary publication · 24994918 (PubMed) · PMC4465252 (PubMed Central)
  144. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM, Wei X, Chen X, Chen Z, Beres JM, Zhang J, Tsao JL, Brenner MC, Zhang Y, Fan C, DePinho RA, Paik J, Gygi SP, Kaelin WG, Zhang Q (2014) Genes Dev 28(13): 1429-44
    › Primary publication · 24990963 (PubMed) · PMC4083087 (PubMed Central)
  145. Cardiology patient page. Breast cancer chemotherapy and your heart. Unitt C, Montazeri K, Tolaney S, Moslehi J (2014) Circulation 129(25): e680-2
    › Primary publication · 24958758 (PubMed)
  146. Survivorship: fatigue, version 1.2014. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D (2014) J Natl Compr Canc Netw 12(6): 876-87
    › Primary publication · 24925198 (PubMed) · PMC4465265 (PubMed Central)
  147. Survivorship: sleep disorders, version 1.2014. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D, National Comprehensive Cancer Network (2014) J Natl Compr Canc Netw 12(5): 630-42
    › Primary publication · 24812132 (PubMed) · PMC4771023 (PubMed Central)
  148. Survivorship: pain version 1.2014. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D, National Comprehensive Cancer Network (2014) J Natl Compr Canc Netw 12(4): 488-500
    › Primary publication · 24717568 (PubMed) · PMC4465256 (PubMed Central)
  149. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK (2014) Genes Dev 28(5): 479-90
    › Primary publication · 24589777 (PubMed) · PMC3950345 (PubMed Central)
  150. Heart failure and breast cancer therapies: moving towards personalized risk assessment. Francis SA, Cheng S, Arteaga CL, Moslehi J (2014) J Am Heart Assoc 3(1): e000780
    › Primary publication · 24584746 (PubMed) · PMC3959702 (PubMed Central)
  151. Real-time three-dimensional transoesophageal echocardiography enables preoperative pulmonary valvulopathy assessment. Waller AH, Chatzizisis YS, Moslehi JJ, Chen FY, Mangion JR (2014) Eur Heart J Cardiovasc Imaging 15(6): 713
    › Primary publication · 24378480 (PubMed)
  152. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA (2013) Cell 155(7): 1624-38
    › Primary publication · 24360282 (PubMed) · PMC4076149 (PubMed Central)
  153. Cancer-drug discovery and cardiovascular surveillance. Groarke JD, Cheng S, Moslehi J (2013) N Engl J Med 369(19): 1779-81
    › Primary publication · 24180496 (PubMed)
  154. Cancer cachexia: getting to the heart of the matter. Groarke JD, Cheng S, Jones LW, Moslehi J (2019) Eur Heart J 40(40): e17-e19
    › Primary publication · 24126874 (PubMed) · PMC6801934 (PubMed Central)
  155. A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease. Liu D, Wang CJ, Judge DP, Halushka MK, Ni J, Habashi JP, Moslehi J, Bedja D, Gabrielson KL, Xu H, Qian F, Huso D, Dietz HC, Germino GG, Watnick T (2014) J Am Soc Nephrol 25(1): 81-91
    › Primary publication · 24071006 (PubMed) · PMC3871766 (PubMed Central)
  156. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Icli B, Wara AK, Moslehi J, Sun X, Plovie E, Cahill M, Marchini JF, Schissler A, Padera RF, Shi J, Cheng HW, Raghuram S, Arany Z, Liao R, Croce K, MacRae C, Feinberg MW (2013) Circ Res 113(11): 1231-41
    › Primary publication · 24047927 (PubMed) · PMC4068743 (PubMed Central)
  157. Emerging paradigms in cardiomyopathies associated with cancer therapies. Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ (2013) Circ Res 113(6): 754-64
    › Primary publication · 23989717 (PubMed) · PMC4046703 (PubMed Central)
  158. Cardio-oncology: it takes two to translate. Moslehi J, Cheng S (2013) Sci Transl Med 5(187): 187fs20
    › Primary publication · 23720578 (PubMed)
  159. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J (2014) Eur Heart J 35(10): 612-23
    › Primary publication · 23666251 (PubMed) · PMC3945797 (PubMed Central)
  160. The cardiovascular perils of cancer survivorship. Moslehi J (2013) N Engl J Med 368(11): 1055-6
    › Primary publication · 23484833 (PubMed)
  161. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Bair SM, Choueiri TK, Moslehi J (2013) Trends Cardiovasc Med 23(4): 104-13
    › Primary publication · 23290365 (PubMed) · PMC3621011 (PubMed Central)
  162. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, Pierre-Mongeon F, Heydari B, Francis SA, Moslehi J, Kwong RY, Jerosch-Herold M (2013) Am J Cardiol 111(5): 717-22
    › Primary publication · 23228924 (PubMed) · PMC3578020 (PubMed Central)
  163. Breast cancer therapies and cardiomyopathy. Groarke J, Tong D, Khambhati J, Cheng S, Moslehi J (2012) Med Clin North Am 96(5): 1001-19
    › Primary publication · 22980061 (PubMed)
  164. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, Moslehi J, Kwong RY (2012) Am J Cardiol 110(11): 1679-86
    › Primary publication · 22917553 (PubMed) · PMC3496816 (PubMed Central)
  165. Management of antiangiogenic therapy-induced hypertension. de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD (2012) Hypertension 60(3): 607-15
    › Primary publication · 22851729 (PubMed) · PMC3421063 (PubMed Central)
  166. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Querbes W, Bogorad RL, Moslehi J, Wong J, Chan AY, Bulgakova E, Kuchimanchi S, Akinc A, Fitzgerald K, Koteliansky V, Kaelin WG (2012) Blood 120(9): 1916-22
    › Primary publication · 22611156 (PubMed) · PMC3433093 (PubMed Central)
  167. Telomeres and mitochondria in the aging heart. Moslehi J, DePinho RA, Sahin E (2012) Circ Res 110(9): 1226-37
    › Primary publication · 22539756 (PubMed) · PMC3718635 (PubMed Central)
  168. You can't run from inflammation: lower extremity ischemia, hypoxia signaling, and macrophage subtypes. Moslehi J, Libby P (2012) Circ Res 110(8): 1045-6
    › Primary publication · 22499897 (PubMed)
  169. Reversible cardiomyopathy associated with sunitinib and sorafenib. Uraizee I, Cheng S, Moslehi J (2011) N Engl J Med 365(17): 1649-50
    › Primary publication · 22030001 (PubMed)
  170. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Nazer B, Humphreys BD, Moslehi J (2011) Circulation 124(15): 1687-91
    › Primary publication · 21986775 (PubMed)
  171. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK (2011) J Clin Oncol 29(25): 3450-6
    › Primary publication · 21810682 (PubMed)
  172. Telomere dysfunction induces metabolic and mitochondrial compromise. Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA (2011) Nature 470(7334): 359-65
    › Primary publication · 21307849 (PubMed) · PMC3741661 (PubMed Central)
  173. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG (2010) Circulation 122(10): 1004-16
    › Primary publication · 20733101 (PubMed) · PMC2971656 (PubMed Central)
  174. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG (2009) Mol Cell Biol 29(21): 5729-41
    › Primary publication · 19720742 (PubMed) · PMC2772748 (PubMed Central)
  175. Paragangliomas: etiology, presentation, and management. Joynt KE, Moslehi JJ, Baughman KL (2009) Cardiol Rev 17(4): 159-64
    › Primary publication · 19525677 (PubMed)
  176. Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature. Sung AD, Cheng S, Moslehi J, Scully EP, Prior JM, Loscalzo J (2008) Am J Cardiol 102(5): 643-5
    › Primary publication · 18721529 (PubMed)
  177. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG (2008) Blood 111(6): 3236-44
    › Primary publication · 18096761 (PubMed) · PMC2265460 (PubMed Central)
  178. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA (2005) Circ Res 96(1): 100-9
    › Primary publication · 15576651 (PubMed)
  179. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ (2002) Mol Cell Biol 22(6): 1947-60
    › Primary publication · 11865071 (PubMed) · PMC135590 (PubMed Central)
  180. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, Kaelin WG (2002) EMBO Rep 3(2): 177-82
    › Primary publication · 11818338 (PubMed) · PMC1083969 (PubMed Central)
  181. Posterior urethral valves presented at birth despite normal prenatal ultrasound scans. Moslehi J, Herndon CD, McKenna PH (2001) Urology 57(6): 1178
    › Primary publication · 11377342 (PubMed)
  182. Perforin protects against autoimmunity in lupus-prone mice. Peng SL, Moslehi J, Robert ME, Craft J (1998) J Immunol 160(2): 652-60
    › Primary publication · 9551899 (PubMed)
  183. Influence of antigen organization on the development of lupus autoantibodies. Fatenejad S, Bennett M, Moslehi J, Craft J (1998) Arthritis Rheum 41(4): 603-12
    › Primary publication · 9550469 (PubMed)
  184. Roles of interferon-gamma and interleukin-4 in murine lupus. Peng SL, Moslehi J, Craft J (1997) J Clin Invest 99(8): 1936-46
    › Primary publication · 9109438 (PubMed) · PMC508018 (PubMed Central)